Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial
{{output}}
Background: The efficacy and safety of bictegravir-based antiretroviral therapy in people with HIV and tuberculosis has not been evaluated. We aimed to evaluate the efficacy, safety, and pharmacokinetics of bictegravir-emtricitab... ...
